Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos
A
A
Papadhimitriou
S I
SI
Kritikou-Griva
E
E
Georgiakaki
M
M
Anagnostopoulos
N I
NI
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009101:Multiple Myeloma / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate